Shanghai MicuRx Pharmaceutical Co., Ltd. (SHA:688373)
China · Delayed Price · Currency is CNY 7.19
+0.06 (0.84%)
At close: Aug 29, 2025
SHA:688373 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2020 |
| 136.5 | 130.27 | 90.78 | 48.21 | 7.66 | - | Upgrade | |
Revenue Growth (YoY) | 24.77% | 43.51% | 88.31% | 529.33% | - | - | Upgrade |
Cost of Revenue | 21.36 | 22.41 | 16.7 | 8.82 | 0.76 | - | Upgrade |
Gross Profit | 115.14 | 107.87 | 74.08 | 39.38 | 6.9 | - | Upgrade |
Selling, General & Admin | 171.14 | 176.79 | 168.57 | 146.18 | 124.38 | 42.09 | Upgrade |
Research & Development | 318.81 | 368.56 | 344.86 | 150.39 | 151.76 | 53.03 | Upgrade |
Other Operating Expenses | 0.97 | 0.41 | 0.3 | 0.14 | 0.03 | 0.35 | Upgrade |
Operating Expenses | 491.83 | 546.53 | 514.06 | 296.9 | 276.2 | 95.46 | Upgrade |
Operating Income | -376.69 | -438.66 | -439.98 | -257.52 | -269.3 | -95.46 | Upgrade |
Interest Expense | -12.46 | -11.15 | -10.14 | -8.82 | -5.23 | -2.44 | Upgrade |
Interest & Investment Income | 2.61 | 2.37 | 2.19 | 4.4 | 2.39 | 1 | Upgrade |
Currency Exchange Gain (Loss) | -1.8 | -4.52 | 0.02 | -5.59 | -0.29 | -0 | Upgrade |
Other Non Operating Income (Expenses) | -1.4 | -1 | -0.13 | 0.34 | -0.4 | -0.03 | Upgrade |
EBT Excluding Unusual Items | -389.73 | -452.96 | -448.03 | -267.19 | -272.82 | -96.93 | Upgrade |
Gain (Loss) on Sale of Investments | 11.41 | 17.08 | 33.34 | 18.49 | 10.53 | -0.14 | Upgrade |
Gain (Loss) on Sale of Assets | 0.03 | 0.03 | 0 | 0.49 | -0.02 | -0 | Upgrade |
Asset Writedown | - | - | - | - | - | -0.01 | Upgrade |
Other Unusual Items | 1.76 | 1.34 | -0.46 | 27.92 | 36.08 | 10.76 | Upgrade |
Pretax Income | -376.52 | -434.51 | -415.15 | -220.29 | -226.23 | -86.32 | Upgrade |
Income Tax Expense | 1.57 | 6.21 | 5.97 | 0.01 | 0.04 | 0.01 | Upgrade |
Net Income | -378.09 | -440.72 | -421.12 | -220.3 | -226.27 | -86.33 | Upgrade |
Net Income to Common | -378.09 | -440.72 | -421.12 | -220.3 | -226.27 | -86.33 | Upgrade |
Shares Outstanding (Basic) | 661 | 656 | 656 | 580 | 526 | 255 | Upgrade |
Shares Outstanding (Diluted) | 661 | 656 | 656 | 580 | 526 | 255 | Upgrade |
Shares Change (YoY) | 1.55% | - | 13.09% | 10.17% | 106.16% | 12.82% | Upgrade |
EPS (Basic) | -0.57 | -0.67 | -0.64 | -0.38 | -0.43 | -0.34 | Upgrade |
EPS (Diluted) | -0.57 | -0.67 | -0.64 | -0.38 | -0.43 | -0.34 | Upgrade |
Free Cash Flow | -339.99 | -448.1 | -336.74 | -252.18 | -203.89 | -90.14 | Upgrade |
Free Cash Flow Per Share | -0.51 | -0.68 | -0.51 | -0.43 | -0.39 | -0.35 | Upgrade |
Gross Margin | 84.35% | 82.80% | 81.61% | 81.70% | 90.08% | - | Upgrade |
Operating Margin | -275.95% | -336.72% | -484.69% | -534.19% | -3515.62% | - | Upgrade |
Profit Margin | -276.98% | -338.31% | -463.91% | -456.99% | -2953.91% | - | Upgrade |
Free Cash Flow Margin | -249.07% | -343.97% | -370.96% | -523.13% | -2661.81% | - | Upgrade |
EBITDA | -374.66 | -436.4 | -437.97 | -256.22 | -268.75 | -94.99 | Upgrade |
D&A For EBITDA | 2.03 | 2.26 | 2.02 | 1.29 | 0.55 | 0.47 | Upgrade |
EBIT | -376.69 | -438.66 | -439.98 | -257.52 | -269.3 | -95.46 | Upgrade |
Revenue as Reported | 136.5 | 130.27 | 90.78 | 48.21 | 7.66 | - | Upgrade |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.